These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31357873)

  • 1. ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
    Asenjo García B; Navarro Guirado F; Nagib Raya F; Vidal Denis M; Bravo Rodríguez F; Galán Montenegro P
    Acta Radiol; 2020 Mar; 61(3):404-413. PubMed ID: 31357873
    [No Abstract]   [Full Text] [Related]  

  • 2. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosed recurrent glioma and antiangiogenic treatment response by 11C-Methionine PET.
    García JR; Baquero M; Bassa P; Soler M; Moragas M; Riera E
    Rev Esp Med Nucl Imagen Mol; 2015; 34(6):398-9. PubMed ID: 26092078
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis.
    Kurokawa R; Baba A; Kurokawa M; Capizzano A; Hassan O; Johnson T; Ota Y; Kim J; Hagiwara A; Moritani T; Srinivasan A
    AJNR Am J Neuroradiol; 2022 Feb; 43(2):202-206. PubMed ID: 35058300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI Biomarkers of Bevacizumab Therapy Correlate with Progression-Free Survival but Not Overall Survival in Recurrent Glioblastoma.
    Dillon WP
    Radiology; 2020 Oct; 297(1):176-177. PubMed ID: 32726196
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
    Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
    Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.
    Chang K; Zhang B; Guo X; Zong M; Rahman R; Sanchez D; Winder N; Reardon DA; Zhao B; Wen PY; Huang RY
    Neuro Oncol; 2016 Dec; 18(12):1680-1687. PubMed ID: 27257279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.
    Grossmann P; Narayan V; Chang K; Rahman R; Abrey L; Reardon DA; Schwartz LH; Wen PY; Alexander BM; Huang R; Aerts HJWL
    Neuro Oncol; 2017 Nov; 19(12):1688-1697. PubMed ID: 28499022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
    Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
    Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
    Ellingson BM; Hagiwara A; Morris CJ; Cho NS; Oshima S; Sanvito F; Oughourlian TC; Telesca D; Raymond C; Abrey LE; Garcia J; Aftab DT; Hessel C; Rachmilewitz Minei T; Harats D; Nathanson DA; Wen PY; Cloughesy TF
    Clin Cancer Res; 2023 Oct; 29(20):4186-4195. PubMed ID: 37540556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
    Schell M; Pflüger I; Brugnara G; Isensee F; Neuberger U; Foltyn M; Kessler T; Sahm F; Wick A; Nowosielski M; Heiland S; Weller M; Platten M; Maier-Hein KH; Von Deimling A; Van Den Bent MJ; Gorlia T; Wick W; Bendszus M; Kickingereder P
    Neuro Oncol; 2020 Nov; 22(11):1667-1676. PubMed ID: 32393964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
    Auer TA; Renovanz M; Marini F; Brockmann MA; Tanyildizi Y
    J Neurooncol; 2017 Jul; 133(3):571-579. PubMed ID: 28555422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.
    Bonekamp D; Mouridsen K; Radbruch A; Kurz FT; Eidel O; Wick A; Schlemmer HP; Wick W; Bendszus M; Østergaard L; Kickingereder P
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):485-494. PubMed ID: 26861817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.
    Nguyen HS; Milbach N; Hurrell SL; Cochran E; Connelly J; Bovi JA; Schultz CJ; Mueller WM; Rand SD; Schmainda KM; LaViolette PS
    AJNR Am J Neuroradiol; 2016 Dec; 37(12):2201-2208. PubMed ID: 27492073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.